236 related articles for article (PubMed ID: 36920664)
21. Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
Kim M; Kim S; Park YW; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
J Neurooncol; 2022 Sep; 159(3):695-703. PubMed ID: 35988090
[TBL] [Abstract][Full Text] [Related]
22. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
24. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
[TBL] [Abstract][Full Text] [Related]
27. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
28. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.
Sommerlath VN; Buergy D; Etminan N; Brehmer S; Reuss D; Sarria GR; Guiot MC; Hänggi D; Wenz F; Petrecca K; Giordano FA
Radiat Oncol; 2022 Jan; 17(1):15. PubMed ID: 35073955
[TBL] [Abstract][Full Text] [Related]
29. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
31. Association of
Kim M; Yoo J; Chang JH; Kim SH
Anticancer Res; 2022 Jan; 42(1):335-341. PubMed ID: 34969742
[TBL] [Abstract][Full Text] [Related]
32. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
34. [Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].
Kamoshima Y; Motegi H; Terasaka S; Kobayashi H; Yamaguchi S; Murata J; Tanaka S; Houkin K
No Shinkei Geka; 2012 Feb; 40(2):129-35. PubMed ID: 22281465
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.
Reifenberger G; Weber RG; Riehmer V; Kaulich K; Willscher E; Wirth H; Gietzelt J; Hentschel B; Westphal M; Simon M; Schackert G; Schramm J; Matschke J; Sabel MC; Gramatzki D; Felsberg J; Hartmann C; Steinbach JP; Schlegel U; Wick W; Radlwimmer B; Pietsch T; Tonn JC; von Deimling A; Binder H; Weller M; Loeffler M;
Int J Cancer; 2014 Oct; 135(8):1822-31. PubMed ID: 24615357
[TBL] [Abstract][Full Text] [Related]
36. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
37. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
38. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A
Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
[TBL] [Abstract][Full Text] [Related]
40. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
